NEW YORK (GenomeWeb News) – Trovagene today said it has licensed to Quest Diagnostics non-exclusive rights to incorporate the nucleophosmin protein (NPM1) into its research and testing services for acute myelogenous leukemia.

The San Diego-based molecular diagnostics firm holds the exclusive worldwide rights to an issued US patent, as well as patent applications in the US and elsewhere, covering NPM. It has licensed non-exclusive rights to the marker to several diagnostic and lab testing firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.